[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"respiratory-distress-syndrome-of-newborn\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:respiratory-distress-syndrome-of-newborn":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,55],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":29,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":4},"100635248","surfactant-administration-methods-in-preterm-infants-with-rds-a-swedish-cohort-study-100635248",false,"NCT07550218","Surfactant Administration Methods in Preterm Infants With RDS: A Swedish Cohort Study","A Prospective Observational Study of Surfactant AdministrationMethods for Preterm Infants With Respiratory Distress SyndromeWith Long-term Follow-up in the Swedish Neonatal Quality Register","Inclusion Criteria:\n\n* Patient has received surfactant by any administration method\n* Gestational age below 37 weeks'\n* First surfactant treatment given before 48 hours of age\n* Confirmed or suspected diagnosis of respiratory distress syndrome (RDS)\n\nExclusion Criteria:\n\n• Not fulfilling above inclusion criteria","ALL",{"count":18,"type":19},300,"ESTIMATED","6 Years","OBSERVATIONAL","The goal of this observational study is to evaluate different methods of surfactant administration in preterm infants with respiratory distress syndrome (RDS). Preterm infants often have immature lungs and a deficiency of surfactant, a substance that helps keep the lungs open and supports oxygen exchange.Surfactant can be delivered to the lungs using different techniques, including INSURE (brief intubation), LISA (via a thin catheter), SALSA (via a laryngeal mask airway), and traditional administration via endotracheal intubation followed by mechanical ventilation. The main question this study aims to answer is:Which method of surfactant administration is associated with better clinical outcomes in preterm infants with RDS?The study will prospectively collect clinical data on infants receiving surfactant as part of standard care, with long-term follow-up using data from the Swedish Neonatal Quality Register. The results are intended to be used to inform the design of a future randomized multicenter study.",[24,25,26,27,28],"Respiratory Distress Syndrome (& [Hyaline Membrane Disease])","Respiratory Distress Syndrome (Neonatal)","Respiratory Distress Syndrome (RDS)","Respiratory Distress Syndrome of Newborn","Respiratory Distress Syndrome in Premature Infant",[30,31,32,33,34,35,36,37,38,39,40,41,42],"Preterm infants","Premature infants","Surfactant therapy","Supraglottic Airway","Laryngeal Mask Airway","Intubation","LISA","INSURE","Less Invasive Surfactant Therapy","SALSA","Surfactant via Laryngeal or Supraglottic Airway","RDS","Respiratory Distress Syndrome","NOT_YET_RECRUITING","2026-04-17",{"date":46,"type":47},"2026-04-24","ACTUAL",{"date":49,"type":19},"2026-04-27",{"date":51,"type":19},"2029-08-27",{"name":53,"class":54},"Vastra Gotaland Region","OTHER_GOV",{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":86},"100455231","clinical-pharmacology-of-dexamethasone-in-pregnant-women-with-preterm-labor-100455231","NCT05207852","Clinical Pharmacology of Dexamethasone in Pregnant Women With Preterm Labor","Inclusion Criteria:\n\n* Aged 20-40 (inclusive);\n* Body mass Index (BMI) 18.5-27.9kg \u002Fm2 (inclusive)\n* Single and twin pregnancy;\n* Premature delivery at 24-36 weeks;\n* No antibiotics, prebiotics or probiotics were used one month before feces collection (such as Bifidobacterium triplex live powder, Lactobacillus acidophilus tablet, compound Lactobacillus acidophilus tablet, Bacillus subtilis diplex live intestinal capsule, etc.);\n* Preeclampsia patients accounted for about 1\u002F10 of each group;\n* Use dexamethasone I.M. 5mg Q12h regimen (or other dexamethasone administration regimen) to promote fetal lung maturation.\n\nExclusion Criteria:\n\n* Ectopic pregnancy;\n* Suffering from diabetes, fetal distress, serious infectious diseases (such as sepsis, septic shock), fever;\n* Those who have taken glucocorticoid drugs within 2 weeks before joining the clinical trial;\n* Those who took clindamycin during the study period;\n* Congenital fetal malformation or fetal hypoxia in early pregnancy;\n* Convulsive patients;\n* HIV\u002FHCV\u002F HEPATITIS A, drug abuse history;\n* Suffering from chorioamnitis, endometritis;\n* Placental abruption, severe intrauterine bleeding;\n* Pregnant women whose cervical dilation is greater than or equal to 4 cm or whose cervical length is less than or equal to 20 mm by ultrasound examination;\n* Pregnant women who took food or drugs during the study that might affect the safety of the fetus;\n* Pregnant women participating in other clinical trials.","FEMALE","20 Years","40 Years",{"count":65,"type":19},288,"This study through to the pregnant woman blood concentrations of dexamethasone therapy after research, explore the pharmacokinetic data of dexamethasone in pregnant women, Chinese pregnant women dexamethasone pharmacokinetic model, provide a reference for the clinical use of dexamethasone dose, through the biomarkers of dexamethasone to promote fetal lung maturity and other metabolomics, It provides the basis for the effectiveness and safety study of dexamethasone.",[27,68],"Threatened Premature Labor, Antepartum",[70,71,72,73,74],"Dexamethasone","Pregnancy","Preterm","Quantitative pharmacology","P-glycoprotein","RECRUITING","2022-01-24",{"date":78,"type":47},"2022-01-26",{"date":80,"type":47},"2021-12-01",{"date":82,"type":19},"2027-12-31",{"name":84,"class":85},"Dongyang Liu","OTHER",1]